IP Library Granted Patent US 8,048,439
Granted Patent B2
US 8,048,439 · App. 11/128,265 · Granted Nov 1, 2011

Therapeutic foam

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,439
App. No.
11/128,265
Granted
Nov 1, 2011
Kind
B2
Abstract

A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Claims (12)

1. A method for angiologic treatment comprising injecting a foam comprising a liquid phase and a gas phase wherein

the liquid phase comprises at least one sclerosing agent and

the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume, xenon gas in an amount greater than 5% and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen into veins to be treated.

2. The method of claim 1 comprising having a patient breathe oxygen or an oxygen enriched atmosphere prior to injecting the foam.

3. The method for phlebologic treatment comprising injecting a foam comprising a liquid phase and a gas phase wherein

the liquid phase comprises at least one sclerosing agent and

the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume, xenon gas in an amount greater than 5% and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen into veins to be treated.

4. The method of claim 3 comprising having a patient breathe oxygen or an oxygen enriched atmosphere prior to injecting the foam.

5. The method of claim 4 , wherein a greater saphenous vein of one leg of a human patient is treated by a single injection of foam.

6. The method of claim 5 , wherein the single injection uses an amount ranging from 10 ml to 50 ml.

7. The method of claim 6 , wherein the single injection uses an amount ranging from 10 ml to 40 ml.

8. The method of claim 7 , wherein the single injection uses an amount ranging from 15 ml to 30 ml.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: BTG INTERNATIONAL LIMITED
To: PROVENSIS LIMITED
Reel/Frame 065731/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: PROVENSIS LIMITED
To: BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED
Reel/Frame 065742/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2008
From: MOGGRIDGE, GEOFFREY D.; VAN LIEW, HUGH; JENKINS, WILLIAM J.
To: BTG INTERNATIONAL LTD.
Reel/Frame 020381/0667 →